1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Target EGFR
1.2.3 Target ALK
1.2.4 Target HER2
1.2.5 Target ROS1
1.2.6 Target BRAF
1.2.7 Target MEK
1.2.8 Target VEGFR2
1.2.9 Target VEGF
1.2.10 Target MET
1.3 Market by Application
1.3.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Targeted Drugs for NSCLC Market Perspective (2017-2028)
2.2 Targeted Drugs for NSCLC Growth Trends by Region
2.2.1 Targeted Drugs for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Targeted Drugs for NSCLC Historic Market Size by Region (2017-2022)
2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Region (2023-2028)
2.3 Targeted Drugs for NSCLC Market Dynamics
2.3.1 Targeted Drugs for NSCLC Industry Trends
2.3.2 Targeted Drugs for NSCLC Market Drivers
2.3.3 Targeted Drugs for NSCLC Market Challenges
2.3.4 Targeted Drugs for NSCLC Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2017-2022)
3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2017-2022)
3.2 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
3.4 Global Targeted Drugs for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2021
3.5 Targeted Drugs for NSCLC Key Players Head office and Area Served
3.6 Key Players Targeted Drugs for NSCLC Product Solution and Service
3.7 Date of Enter into Targeted Drugs for NSCLC Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Targeted Drugs for NSCLC Breakdown Data by Type
4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2017-2022)
4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2023-2028) 5 Targeted Drugs for NSCLC Breakdown Data by Application
5.1 Global Targeted Drugs for NSCLC Historic Market Size by Application (2017-2022)
5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Targeted Drugs for NSCLC Market Size (2017-2028)
6.2 North America Targeted Drugs for NSCLC Market Size by Type
6.2.1 North America Targeted Drugs for NSCLC Market Size by Type (2017-2022)
6.2.2 North America Targeted Drugs for NSCLC Market Size by Type (2023-2028)
6.2.3 North America Targeted Drugs for NSCLC Market Share by Type (2017-2028)
6.3 North America Targeted Drugs for NSCLC Market Size by Application
6.3.1 North America Targeted Drugs for NSCLC Market Size by Application (2017-2022)
6.3.2 North America Targeted Drugs for NSCLC Market Size by Application (2023-2028)
6.3.3 North America Targeted Drugs for NSCLC Market Share by Application (2017-2028)
6.4 North America Targeted Drugs for NSCLC Market Size by Country
6.4.1 North America Targeted Drugs for NSCLC Market Size by Country (2017-2022)
6.4.2 North America Targeted Drugs for NSCLC Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada 7 Europe
7.1 Europe Targeted Drugs for NSCLC Market Size (2017-2028)
7.2 Europe Targeted Drugs for NSCLC Market Size by Type
7.2.1 Europe Targeted Drugs for NSCLC Market Size by Type (2017-2022)
7.2.2 Europe Targeted Drugs for NSCLC Market Size by Type (2023-2028)
7.2.3 Europe Targeted Drugs for NSCLC Market Share by Type (2017-2028)
7.3 Europe Targeted Drugs for NSCLC Market Size by Application
7.3.1 Europe Targeted Drugs for NSCLC Market Size by Application (2017-2022)
7.3.2 Europe Targeted Drugs for NSCLC Market Size by Application (2023-2028)
7.3.3 Europe Targeted Drugs for NSCLC Market Share by Application (2017-2028)
7.4 Europe Targeted Drugs for NSCLC Market Size by Country
7.4.1 Europe Targeted Drugs for NSCLC Market Size by Country (2017-2022)
7.4.2 Europe Targeted Drugs for NSCLC Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size (2017-2028)
8.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type
8.2.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Targeted Drugs for NSCLC Market Share by Type (2017-2028)
8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application
8.3.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Targeted Drugs for NSCLC Market Share by Application (2017-2028)
8.4 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region
8.4.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia 9 Latin America
9.1 Latin America Targeted Drugs for NSCLC Market Size (2017-2028)
9.2 Latin America Targeted Drugs for NSCLC Market Size by Type
9.2.1 Latin America Targeted Drugs for NSCLC Market Size by Type (2017-2022)
9.2.2 Latin America Targeted Drugs for NSCLC Market Size by Type (2023-2028)
9.2.3 Latin America Targeted Drugs for NSCLC Market Share by Type (2017-2028)
9.3 Latin America Targeted Drugs for NSCLC Market Size by Application
9.3.1 Latin America Targeted Drugs for NSCLC Market Size by Application (2017-2022)
9.3.2 Latin America Targeted Drugs for NSCLC Market Size by Application (2023-2028)
9.3.3 Latin America Targeted Drugs for NSCLC Market Share by Application (2017-2028)
9.4 Latin America Targeted Drugs for NSCLC Market Size by Country
9.4.1 Latin America Targeted Drugs for NSCLC Market Size by Country (2017-2022)
9.4.2 Latin America Targeted Drugs for NSCLC Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size (2017-2028)
10.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type
10.2.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Targeted Drugs for NSCLC Market Share by Type (2017-2028)
10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application
10.3.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Targeted Drugs for NSCLC Market Share by Application (2017-2028)
10.4 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country
10.4.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE 11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Allergan Business Overview
11.1.3 Allergan Targeted Drugs for NSCLC Introduction
11.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.1.5 Allergan Recent Developments
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Targeted Drugs for NSCLC Introduction
11.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.2.5 Amgen Recent Developments
11.3 ARIAD Pharmaceuticals (Takeda)
11.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
11.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
11.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.3.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
11.4 Beacon Pharma Limited
11.4.1 Beacon Pharma Limited Company Details
11.4.2 Beacon Pharma Limited Business Overview
11.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
11.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.4.5 Beacon Pharma Limited Recent Developments
11.5 BeiGene
11.5.1 BeiGene Company Details
11.5.2 BeiGene Business Overview
11.5.3 BeiGene Targeted Drugs for NSCLC Introduction
11.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.5.5 BeiGene Recent Developments
11.6 Biocon
11.6.1 Biocon Company Details
11.6.2 Biocon Business Overview
11.6.3 Biocon Targeted Drugs for NSCLC Introduction
11.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.6.5 Biocon Recent Developments
11.7 Boehringer-Ingelheim
11.7.1 Boehringer-Ingelheim Company Details
11.7.2 Boehringer-Ingelheim Business Overview
11.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
11.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.7.5 Boehringer-Ingelheim Recent Developments
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
11.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.8.5 Celgene Corporation Recent Developments
11.9 Drug International Limted
11.9.1 Drug International Limted Company Details
11.9.2 Drug International Limted Business Overview
11.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
11.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.9.5 Drug International Limted Recent Developments
11.10 Fujifilm Kyowa Kirin Biologics
11.10.1 Fujifilm Kyowa Kirin Biologics Company Details
11.10.2 Fujifilm Kyowa Kirin Biologics Business Overview
11.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
11.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.10.5 Fujifilm Kyowa Kirin Biologics Recent Developments
11.11 Genvio Pharma Limited
11.11.1 Genvio Pharma Limited Company Details
11.11.2 Genvio Pharma Limited Business Overview
11.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
11.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.11.5 Genvio Pharma Limited Recent Developments
11.12 Hetero Drugs
11.12.1 Hetero Drugs Company Details
11.12.2 Hetero Drugs Business Overview
11.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
11.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.12.5 Hetero Drugs Recent Developments
11.13 ImClone Systems ?(Eli Lilly)
11.13.1 ImClone Systems ?(Eli Lilly) Company Details
11.13.2 ImClone Systems ?(Eli Lilly) Business Overview
11.13.3 ImClone Systems ?(Eli Lilly) Targeted Drugs for NSCLC Introduction
11.13.4 ImClone Systems ?(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.13.5 ImClone Systems ?(Eli Lilly) Recent Developments
11.14 Incepta Pharmaceuticals
11.14.1 Incepta Pharmaceuticals Company Details
11.14.2 Incepta Pharmaceuticals Business Overview
11.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.14.5 Incepta Pharmaceuticals Recent Developments
11.15 Mylan
11.15.1 Mylan Company Details
11.15.2 Mylan Business Overview
11.15.3 Mylan Targeted Drugs for NSCLC Introduction
11.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.15.5 Mylan Recent Developments
11.16 Novartis
11.16.1 Novartis Company Details
11.16.2 Novartis Business Overview
11.16.3 Novartis Targeted Drugs for NSCLC Introduction
11.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.16.5 Novartis Recent Developments
11.17 Pfizer
11.17.1 Pfizer Company Details
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Targeted Drugs for NSCLC Introduction
11.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.17.5 Pfizer Recent Developments
11.18 Reliance Lifesciences
11.18.1 Reliance Lifesciences Company Details
11.18.2 Reliance Lifesciences Business Overview
11.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
11.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.18.5 Reliance Lifesciences Recent Developments
11.19 Roche
11.19.1 Roche Company Details
11.19.2 Roche Business Overview
11.19.3 Roche Targeted Drugs for NSCLC Introduction
11.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.19.5 Roche Recent Developments
11.20 AstraZeneca
11.20.1 AstraZeneca Company Details
11.20.2 AstraZeneca Business Overview
11.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
11.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.20.5 AstraZeneca Recent Developments
11.21 Cipla
11.21.1 Cipla Company Details
11.21.2 Cipla Business Overview
11.21.3 Cipla Targeted Drugs for NSCLC Introduction
11.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.21.5 Cipla Recent Developments
11.22 Teva
11.22.1 Teva Company Details
11.22.2 Teva Business Overview
11.22.3 Teva Targeted Drugs for NSCLC Introduction
11.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.22.5 Teva Recent Developments
11.23 OSI Pharmaceuticals
11.23.1 OSI Pharmaceuticals Company Details
11.23.2 OSI Pharmaceuticals Business Overview
11.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.23.5 OSI Pharmaceuticals Recent Developments
11.24 Glenmark Pharmaceuticals
11.24.1 Glenmark Pharmaceuticals Company Details
11.24.2 Glenmark Pharmaceuticals Business Overview
11.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.24.5 Glenmark Pharmaceuticals Recent Developments
11.25 Natco Pharma
11.25.1 Natco Pharma Company Details
11.25.2 Natco Pharma Business Overview
11.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
11.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2017-2022)
11.25.5 Natco Pharma Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
